Official PDF Translation•Acta Biochimica et Biophysica Sinica

Glycolysis reprogramming predicts poor prognosis and drives therapy resistance via CLN6 in lethal prostate cancer

Authors: Zhouda Cai; Jianming Lu; Shanshan Mo; Jipu Liu; Chuanfan Zhong; Yongding Wu; Fen Zou; Jianheng Ye; Zhaodong Han; Yuxiang Liang; Le Zhang; Fengping Liu; Weide Zhong

DOI: 10.3724/abbs.2025257Status: Verified Translated Edition

Sponsored AdvertisementAd Placement Area

reCAPTCHA Bot Shield Active

Preparing Secure Academic Download

Verifying human reader & generating high-resolution document...

Verifying Document Integrity15s remaining

← Back to Article

Protected by Google reCAPTCHA v3.•Privacy•Terms

Sponsored ContentAdSense In-Feed Ad Slot

Key Findings in This Report

• Elevated glycolysis activity is associated with poor progression-free and overall survival in lethal prostate cancer. • A glycolysis-based prognostic score (GLY score) effectively stratifies risk and predicts therapy resistance. • Enzalutamide-resistant prostate cancer cells exhibit heightened glycolysis; inhibition with 2-DG restores drug sensitivity. • CLN6 is identified as a novel hub gene in glycolysis, representing a promising therapeutic target.